VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
XGNExagen Inc.
$4.58$111M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksXGNCash Flow

Exagen Inc. (XGN) Cash Flow Statement

13Y historyFree accessUpdated daily

Free cash flow remains erratic, swinging from a positive $8.2 million in 2023Q4 to a negative $10.6 million in 2026Q1, largely driven by volatile working capital requirements.

XGN Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'15Dec'14Dec'13Dec'12
Cash from Operations-13.37M-13.63M-13.28M-14.46M-32.14M-20.27M-14.08M-9.71M-9.3M-10.97M-11.9M-10.77M-6.87M-7.48M
Operating CF Margin %--20.47%-23.87%-27.52%-70.55%-41.97%-33.55%-24.04%-28.67%-40.91%-66.32%-92.37%-224.71%-807.45%
Operating CF Growth %-711.27%-2.61%8.18%55.01%-58.59%-43.92%-45.03%-4.41%15.2%7.85%-10.48%-56.93%8.19%-
Net Income-20.17M-19.95M-15.12M-23.69M-47.39M-26.85M-16.69M-12.04M-8.01M-25.63M-19.18M-14.98M-13.5M-7.32M
Depreciation & Amortization2.28M2.12M1.72M2.17M1.56M948K546K591K731K670K879K558K455K398K
Stock-Based Compensation1.69M2.16M1.76M3.62M4.7M4.73M2.69M572K114K187K287K279K152K116K
Deferred Taxes0000-306K148K-106K-247K31K-554K251K-14K42K42K
Other Non-Cash Items4.46M4.03M1.43M3.12M7.62M819K805K1.24M1.43M16.38M6.76M1.71M5.22M-263K
Working Capital Changes-1.63M-1.98M-3.08M325K1.67M-61K-1.34M174K-3.59M-2.02M-896K1.68M759K-446K
Change in Receivables-1.04M-3.02M-1.28M-474K3.58M-744K-3.19M237K-2.26M-198K055K-55K0
Change in Inventory0000000-567K-497K436K0261K403K0
Change in Payables-230K42K308K67K901K-655K986K528K-824K44K77K1.4M381K-549K
Cash from Investing-747K-626K-515K-804K-4.32M-2.42M-455K-103K-199K-510K-800K-649K549K-1.13M
Capital Expenditures-756K-641K-515K-828K-4.32M-2.37M-455K-403K-199K-567K-805K-649K-172K-440K
CapEx % of Revenue1.11%0.96%0.93%1.58%9.48%4.91%1.08%1%0.61%2.12%4.49%5.56%5.63%47.52%
Acquisitions9K15K00000300K057K5K000
Investments--------------
Other Investing00024K0-50K00057K5K0721K-693K
Cash from Financing24.44M24.43M-663K-10.63M-489K64.68M-97K68.73M11.42M19.16M10.61M8.28M11.31M7.25M
Debt Issued (Net)1.92M2.01M-861K-10.94M-696K-525K-249K-138K4.96M4.51M10.75M8.72M7.4M-550K
Equity Issued (Net)22.52M22.42M198K306K446K69.14M173K68.87M004K195K07.8M
Dividends Paid0000000-6.74M000000
Share Repurchases1K0000000000000
Other Financing0000-239K-3.94M-21K6.74M6.47M14.64M-147K-635K3.91M0
Net Change in Cash10.32M10.18M-14.46M-25.9M-36.95M41.99M-14.64M58.92M1.92M7.68M-2.1M-3.14M5M-1.36M
Free Cash Flow-14.13M-14.27M-13.79M-15.29M-36.46M-22.64M-14.54M-10.11M-9.5M-11.54M-12.71M-11.42M-7.04M-7.92M
FCF Margin %-20.66%-21.43%-24.79%-29.1%-80.03%-46.87%-34.64%-25.04%-29.28%-43.03%-70.81%-97.93%-230.34%-854.97%
FCF Growth %8.57%-3.42%9.78%58.07%-61.06%-55.71%-43.75%-6.46%17.64%9.22%-11.25%-62.31%11.12%-
FCF per Share-0.59-0.66-0.76-0.86-2.13-1.42-1.15-0.81-150.78-183.08-202.35-202.65-131.10-223.61
FCF Conversion (FCF/Net Income)0.70x0.68x0.88x0.61x0.68x0.75x0.84x0.81x1.16x0.43x0.62x0.72x0.51x1.02x
Interest Paid00000000000000
Taxes Paid00000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Limited operational cash runway

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Obscured by Accruals

As reported in recent financial filings, Exagen's operating cash flow frequently diverges from net income, with OCF/NI ratios reaching as high as 2.84 in 2025Q1, suggesting that reported earnings are significantly impacted by non-cash adjustments and timing differences in revenue recognition rather than actual cash generation.

The persistent gap between net income and operating cash flow indicates that the company's accrual-based accounting may be masking the underlying cash burn. Investors should monitor whether these fluctuations in conversion are driven by legitimate timing differences in insurance collections or if they reflect a more structural difficulty in converting diagnostic service revenue into realized cash.

Free Cash Flow Volatility Persists

Based on the provided quarterly data, Exagen's free cash flow trajectory remains highly erratic, swinging from a positive $8.2 million in 2023Q4 to a negative $10.6 million in 2026Q1, which highlights the company's ongoing struggle to achieve a self-sustaining cash flow profile amidst its current growth phase.

The lack of a consistent positive FCF trend suggests that the business model is currently dependent on external capital to bridge the gap between operational expenses and cash receipts. This volatility warrants further investigation into whether the periodic cash inflows are sustainable or merely artifacts of lumpy insurance reimbursement cycles.

Working Capital Swings Drive Burn

According to the cash flow statements, working capital changes have been a primary driver of cash volatility, with a significant $8.1 million outflow in 2025Q1 contrasting with a $10.9 million inflow in 2023Q4, indicating that the company's cash position is highly sensitive to accounts receivable management.

These dramatic swings in working capital suggest that the timing of insurance payments and the complexity of the billing process are creating significant friction in cash conversion. The reliance on these fluctuations to manage liquidity may indicate that the company lacks the operational maturity to stabilize its cash cycle.

Minimal Capital Intensity Observed

As evidenced by the quarterly data, Exagen maintains a low capital intensity, with CapEx/Revenue ratios consistently remaining below 2% over the last ten quarters, suggesting that the company's primary cash requirements are operational rather than driven by heavy investment in physical laboratory infrastructure or equipment.

While the low capital intensity is a positive for cash preservation, it also implies that the company's growth is not being constrained by physical capacity but rather by the high cost of customer acquisition and service delivery. This structure suggests that any future scaling will likely require increased SG&A spend rather than significant capital expenditure.

XGN — Frequently Asked Questions

Quick answers to the most common questions about buying XGN stock.

How much cash does Exagen Inc. (XGN) generate from operations?

Exagen Inc. (XGN) generated $-13.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Exagen Inc.'s free cash flow?

Exagen Inc. (XGN) reported negative free cash flow of $14.3M in 2025, indicating capital requirements exceeded cash from operations.

What is Exagen Inc.'s capital expenditure (CapEx)?

Exagen Inc. (XGN) spent $0.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.